Cargando…
Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival
Current larynx preservation treatments have achieved an improvement of laryngoesophageal dysfunction-free survival (LDS) but lead to significant toxicities and recurrences. At present, there is no evidence to select the group of patients that may benefit from preservation approaches instead of surge...
Autores principales: | de Miguel-Luken, María José, Chaves-Conde, Manuel, Quintana, Begoña, Menoyo, Alicia, Tirado, Isabel, de Miguel-Luken, Verónica, Pachón, Jerónimo, Chinchón, David, Suarez, Vladimir, Carnero, Amancio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077972/ https://www.ncbi.nlm.nih.gov/pubmed/27166270 http://dx.doi.org/10.18632/oncotarget.9172 |
Ejemplares similares
-
MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
por: de Miguel-Luken, María-José, et al.
Publicado: (2015) -
Combining targeted therapeutics in the era of precision medicine
por: Papadatos-Pastos, D, et al.
Publicado: (2015) -
The emerging role of benefit-cost analysis in the regulatory process at EPA.
por: Luken, R A
Publicado: (1985) -
Confrontación de la acción de dos fármacos en el tratamiento intrauterino de vacas repetidoras /
por: Martínez Luken, Gustavo
Publicado: (1983) -
MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy
por: Rivero, Maria, et al.
Publicado: (2018)